Vasculitis & polymyalgia rheumatica
COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis
Authors' conclusion
Vaccination against SARS-CoV-2 has been performed in a high percentage of MCV patients with encouraging safety profile.
Study context
- Population
- Patients with mixed cryoglobulinaemic vasculitis (MCV) referring to participating Italian centres
- Participants
- 416 patients
- Outcome
- SARS-CoV-2 vaccination rate and its safety profile (AEs and disease flares within a month after vaccination)
Methodological detailsmulticentre, interview-based survey
- Multicentre
- Interview-based survey
Main finding
As reported in the abstract
SARS-CoV-2 vaccination
- Not vaccinated
- 7.7%
- Reason for not vaccinating: fear of vaccine side-effects
- 50%
- Reason for not vaccinating: medical decision
- 18.8%
- Unvaccinated more frequently treated with chronic GC
- p=0.049
- Unvaccinated more frequently treated with RTX
- p=0.043
Observational data: associations, not effects.
Safety
Mild and self-limiting adverse events (AEs)
- Mild and self-limiting AEs
- 31.7%
Post-vaccination vasculitis flares · within a month after vaccination
- Vasculitis flares
- 5.3%
- Relapses in patients with peripheral neuropathy
- 40%
- Relapses in patients with skin vasculitis
- 25%
Original publication
COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis. Clin Exp Rheumatol. Published 18 March 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →